Business Wire

QUECTEL-WIRELESS

10.1.2024 18:01:36 CET | Business Wire | Press release

Share
Quectel announces industry-first certification of satellite communication module on Skylo network

CES – Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the successful certification of Quectel's NTN-enabled module, the CC660D-LS, for use on the network by Skylo, the leading non-terrestrial network (NTN) service provider. The module is the first to be certified by Skylo for use on its network and enables seamless and reliable IoT-NTN connectivity for any standard device that incorporates the module and has a view of the sky.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110653580/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel announces industry-first certification of satellite communication module on Skylo network (Photo: Business Wire)

Quectel has developed the CC660D-LS module specifically to provide dependable and efficient, two-way, satellite communication capabilities. With the module's certification on the Skylo network, businesses and organizations can harness the power of Skylo's ubiquitous satellite connectivity to enable IoT applications in remote and challenging environments, ensuring that data is transmitted securely and reliably.

The CC660D-LS module provides a range of flexible connectivity options, encompassing L-band, S-band, and Band 23 connections. Notably, this module is equipped to support 3GPP Release 17 IoT non-terrestrial network (IoT-NTN) connections, reflecting its advanced capabilities. Prioritizing reliable connectivity, the CC660D-LS module excels in facilitating two-way communication. Furthermore, the module extends its support to both IP and Non-IP service networks. This dual capability ensures not only enhanced connectivity but also heightened service availability. The CC660D-LS module stands as a comprehensive solution for robust and versatile connectivity needs.

"We are delighted that Skylo has certified our NTN Satellite Communication Module for its network," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This certification reflects our commitment to delivering high-quality satellite communication solutions to our customers worldwide. By collaborating with Skylo, we enable businesses to unlock new opportunities and achieve their IoT goals, regardless of where they are located."

The Skylo certification process involved rigorous testing and evaluation to ensure that the CC660D-LS module meets stringent quality and performance standards, including 3GPP Release-17 standards and Skylo's Standards Plus qualifications. Skylo's network is designed to provide global coverage, ensuring that IoT devices equipped with Quectel's module can stay connected in areas with limited terrestrial infrastructure.

"We are excited to welcome Quectel's CC660D-LS module to our ecosystem of certified devices," said Dr Andrew Nuttall, CTO and Co-Founder of Skylo. "This certification is a testament to our commitment to providing the most reliable and expansive satellite based IoT connectivity. By partnering with industry leaders like Quectel, we empower device manufacturers of all types to expand their IoT applications, add additional review streams, and deliver a superior customer experience that requires no change in user behavior."

Quectel's CC660D-LS module is suitable for a wide range of applications, including asset tracking, fleet management, agriculture, maritime, and more. The module's compact design and low-power consumption make it an ideal choice for battery-powered IoT devices that require long-term, uninterrupted connectivity.

Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.

IoT developers now can streamline their development process by combining Quectel modules with Quectel's antennas and pre-certification services, effectively reducing both costs and time-to-market for their IoT devices. For the CC660D-LS satellite module, Quectel offers the YECN028AA and YFCA011AA antennas, providing developers with versatile options to enhance connectivity and expedite the deployment of their innovative solutions.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

About Skylo

Skylo Technologies is an NTN service provider based in Mountain View, CA, offering a service that allows cellular modems and devices to connect directly over existing satellites. Devices connected over satellite are managed and served by Skylo’s commercial NTN vRAN, featuring a 3GPP standards-based cloud-native base station and core. Skylo works with existing satellite operators, terrestrial mobile network operators, and device makers to provide subscribers an anywhere, anytime connectivity solution that seamlessly roams between terrestrial and satellite networks. Skylo’s focus is on enabling connected services for people outdoors and connected workflows for machines at work across critical industries such as agriculture, maritime, logistics, mining, and others, in addition to mass-market consumer devices. For more information, visit www.skylo.tech, contact info@skylo.tech, or follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110653580/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye